

Supplemental Table 1. Self-reported symptoms following first and second dose of Pfizer-BioNTech SARS-CoV-2 vaccine, by age.

	Post-Dose 1			Post-Dose 2		
	Age <50 (n = 759)	Age ≥50 (n = 273)	P-value*	Age <50 (n = 759)	Age ≥50 (n = 273)	P-value*
Any symptom, n (%)	473 (62.8)	141 (52.0)	0.002	578 (77.1)	174 (64.0)	<0.001
Any symptom excluding injection site symptoms	341 (45.3)	87 (32.1)	<0.001	556 (74.1)	168 (61.8)	<0.001
Pain at injection site	470 (61.9)	140 (51.3)	0.003	565 (74.4)	170 (62.3)	<0.001
≤2 days	229 (48.7)	71 (50.7)	0.38	295 (52.2)	92 (54.1)	0.86
2-7 days	239 (50.9)	67 (47.9)		265 (46.9)	77 (45.3)	
>7 days	2 (0.4)	2 (1.4)		5 (0.9)	1 (0.6)	
Fever or chills	85 (11.2)	23 (8.4)	0.242	323 (42.6)	87 (31.9)	0.002
≤2 days	4 (4.7)	1 (4.3)	-	12 (3.7)	3 (3.4)	0.16
2-7 days	81 (95.3)	22 (95.7)		311 (96.3)	83 (95.4)	
>7 days	0 (0.0)	0 (0.0)		0 (0.0)	1 (1.1)	
Fatigue or malaise	238 (31.4)	59 (21.6)	0.003	489 (64.6)	137 (50.2)	<0.001
≤2 days	29 (12.2)	7 (11.9)	0.02	71 (14.5)	23 (16.8)	0.07
2-7 days	207 (87.0)	48 (81.4)		409 (83.6)	107 (78.1)	
>7 days	2 (0.8)	4 (6.8)		9 (1.8)	7 (5.1)	
Headache, dizziness or lightheadedness	170 (22.5)	52 (19.0)	0.276	350 (46.3)	101 (37.1)	0.011
≤2 days	23 (13.5)	8 (15.4)	0.79	34 (9.7)	12 (11.9)	0.13
2-7 days	143 (84.1)	42 (80.8)		308 (88.0)	83 (82.2)	
>7 days	4 (2.4)	2 (3.8)		8 (2.3)	6 (5.9)	
Eye, ear, mouth, or throat changes	22 (2.9)	1 (0.4)	0.029	29 (3.8)	5 (1.8)	0.166
≤2 days	5 (22.7)	0 (0.0)	0.83	5 (17.2)	1 (20.0)	0.03
2-7 days	16 (72.7)	1 (100.0)		23 (79.3)	2 (40.0)	
>7 days	1 (4.5)	0 (0.0)		1 (3.4)	2 (40.0)	
Swollen lymph node, skin/nail, or face changes	8 (1.1)	2 (0.7)	0.915	45 (5.9)	12 (4.4)	0.426
≤2 days	2 (25.0)	1 (50.0)	0.56	19 (42.2)	7 (58.3)	0.53
2-7 days	3 (37.5)	0 (0.0)		19 (42.2)	3 (25.0)	
>7 days	3 (37.5)	1 (50.0)		7 (15.6)	2 (16.7)	

Cough, chest, or breathing symptoms	17 (2.2)	3 (1.1)	0.359	24 (3.2)	8 (2.9)	1
≤2 days	5 (29.4)	0 (0.0)	0.27	5 (20.8)	4 (50.0)	0.22
2-7 days	11 (64.7)	2 (66.7)		17 (70.8)	3 (37.5)	
>7 days	1 (5.9)	1 (33.3)		2 (8.3)	1 (12.5)	
Nausea, vomiting, diarrhea, or other digestive symptoms	26 (3.4)	6 (2.2)	0.424	112 (14.8)	27 (9.9)	0.055
≤2 days	4 (15.4)	0 (0.0)	0.33	12 (10.7)	6 (22.2)	0.22
2-7 days	21 (80.8)	5 (83.3)		98 (87.5)	20 (74.1)	
>7 days	1 (3.8)	1 (16.7)		2 (1.8)	1 (3.7)	
Muscle, bone, joint, or nerve symptoms	100 (13.2)	20 (7.4)	0.014	265 (35.0)	65 (23.8)	0.001
≤2 days	12 (12.0)	2 (10.0)	0.26	34 (12.8)	11 (16.9)	0.45
2-7 days	83 (83.0)	15 (75.0)		221 (83.4)	50 (76.9)	
>7 days	5 (5.0)	3 (15.0)		10 (3.8)	4 (6.2)	
Memory or mood change	8 (1.1)	4 (1.5)	0.83	21 (2.8)	5 (1.8)	0.535
≤2 days	2 (25.0)	0 (0.0)	0.52	9 (42.9)	1 (20.0)	0.64
2-7 days	5 (62.5)	3 (75.0)		9 (42.9)	3 (60.0)	
>7 days	1 (12.5)	1 (25.0)		3 (14.3)	1 (20.0)	
Sleep changes	26 (3.4)	7 (2.6)	0.617	85 (11.2)	16 (5.9)	0.015
≤2 days	0 (0.0)	3 (42.9)	0.002	13 (15.3)	5 (31.2)	0.31
2-7 days	25 (96.2)	4 (57.1)		64 (75.3)	10 (62.5)	
>7 days	1 (3.8)	0 (0.0)		8 (9.4)	1 (6.2)	

Listed percentages for each symptom represent percent of entire respective subpopulation. Percentages for duration represent percent of symptomatic subpopulation in each timeframe.

*Chi-Square or ANOVA for comparison of any presence of each symptom and duration of symptoms, respectively.

Supplemental Table 2. Self-reported symptoms following first and second dose of Pfizer-BioNTech SARS-CoV-2 vaccine, by sex.

	Post-Dose 1			Post-Dose 2		
	Male (n = 334)	Female (n = 691)	P-value*	Male (n = 334)	Female (n = 691)	P-value*
Any symptom, n (%)	179 (53.8)	429 (62.7)	0.008	220 (66.3)	527 (77.2)	<0.001
Any symptom excluding injection site symptoms	126 (37.8)	297 (43.4)	0.104	210 (63.3)	509 (74.5)	<0.001
Pain at injection site	177 (53.0)	427 (61.8)	0.009	210 (62.9)	520 (75.3)	<0.001
≤2 days	83 (46.9)	214 (50.1)	0.31	111 (52.9)	271 (52.1)	0.30
2-7 days	94 (53.1)	209 (48.9)		99 (47.1)	243 (46.7)	
>7 days	0 (0.0)	4 (0.9)		0 (0.0)	6 (1.2)	
Fever or chills	38 (11.4)	70 (10.1)	0.616	115 (34.4)	293 (42.5)	0.017
≤2 days	2 (5.3)	3 (4.3)	-	8 (7.0)	7 (2.4)	0.07
2-7 days	36 (94.7)	67 (95.7)		107 (93.0)	285 (97.3)	
>7 days	0 (0.0)	0 (0.0)		0 (0.0)	1 (0.3)	
Fatigue or malaise	85 (25.4)	210 (30.4)	0.118	179 (53.8)	442 (64.1)	0.002
≤2 days	9 (10.6)	27 (12.9)	0.68	20 (11.2)	72 (16.3)	0.16
2-7 days	75 (88.2)	178 (84.8)		156 (87.2)	357 (80.8)	
>7 days	1 (1.2)	5 (2.4)		3 (1.7)	13 (2.9)	
Headache, dizziness or lightheadedness	63 (18.9)	156 (22.6)	0.205	127 (38.1)	321 (46.7)	0.012
≤2 days	7 (11.1)	23 (14.7)	0.21	11 (8.7)	34 (10.6)	0.39
2-7 days	56 (88.9)	127 (81.4)		114 (89.8)	275 (85.7)	
>7 days	0 (0.0)	6 (3.8)		2 (1.6)	12 (3.7)	
Eye, ear, mouth, or throat changes	10 (3.0)	13 (1.9)	0.371	11 (3.3)	22 (3.2)	1.0
≤2 days	1 (10.0)	4 (30.8)	0.29	4 (36.4)	2 (9.1)	0.10
2-7 days	8 (80.0)	9 (69.2)		7 (63.6)	17 (77.3)	
>7 days	1 (10.0)	0 (0.0)		0 (0.0)	3 (13.6)	
Swollen lymph node, skin/nail, or face changes	1 (0.3)	9 (1.3)	0.232	9 (2.7)	48 (6.9)	0.008
≤2 days	0 (0.0)	3 (33.3)	0.44	1 (11.1)	25 (52.1)	0.03
2-7 days	0 (0.0)	3 (33.3)		7 (77.8)	15 (31.2)	
>7 days	1 (100.0)	3 (33.3)		1 (11.1)	8 (16.7)	

Cough, chest, or breathing symptoms	5 (1.5)	15 (2.2)	0.624	3 (0.9)	28 (4.1)	0.01
≤2 days	3 (60.0)	2 (13.3)	0.10	0 (0.0)	8 (28.6)	0.40
2-7 days	2 (40.0)	11 (73.3)		3 (100.0)	17 (60.7)	
>7 days	0 (0.0)	2 (13.3)		0 (0.0)	3 (10.7)	
Nausea, vomiting, diarrhea, or other digestive symptoms	6 (1.8)	25 (3.6)	0.161	30 (9.0)	109 (15.8)	0.004
≤2 days	0 (0.0)	4 (16.0)	0.41	3 (10.0)	15 (13.8)	0.55
2-7 days	6 (100.0)	19 (76.0)		27 (90.0)	91 (83.5)	
>7 days	0 (0.0)	2 (8.0)		0 (0.0)	3 (2.8)	
Muscle, bone, joint, or nerve symptoms	31 (9.3)	88 (12.8)	0.128	83 (24.9)	242 (35.1)	0.001
≤2 days	4 (12.9)	10 (11.4)	0.66	7 (8.4)	38 (15.7)	0.13
2-7 days	26 (83.9)	71 (80.7)		74 (89.2)	192 (79.3)	
>7 days	1 (3.2)	7 (8.0)		2 (2.4)	12 (5.0)	
Memory or mood change	3 (0.9)	9 (1.3)	0.799	8 (2.4)	18 (2.6)	1.0
≤2 days	0 (0.0)	2 (22.2)	0.37	3 (37.5)	7 (38.9)	0.30
2-7 days	3 (100.0)	5 (55.6)		5 (62.5)	7 (38.9)	
>7 days	0 (0.0)	2 (22.2)		0 (0.0)	4 (22.2)	
Sleep changes	10 (3.0)	22 (3.2)	1.0	27 (8.1)	73 (10.6)	0.251
≤2 days	2 (20.0)	1 (4.5)	0.32	3 (11.1)	14 (19.2)	0.28
2-7 days	8 (80.0)	20 (90.9)		23 (85.2)	51 (69.9)	
>7 days	0 (0.0)	1 (4.5)		1 (3.7)	8 (11.0)	

Listed percentages for each symptom represent percent of entire respective subpopulation. Percentages for duration represent percent of symptomatic subpopulation in each timeframe.

*Chi-Square or ANOVA for comparison of any presence of each symptom and duration of symptoms, respectively.

Supplemental Table 3. Self-reported symptoms following first and second dose of Pfizer-BioNTech SARS-CoV-2 vaccine, by infection status.

	Post-Dose 1			Post-Dose 2		
	Infection Naive (n = 949)	Prior Infection (n = 83)	P-value*	Infection Naive (n = 949)	Prior Infection (n = 83)	P-value*
Any symptom, n (%)	557 (59.2)	57 (68.7)	0.116	690 (73.5)	62 (74.7)	0.912
Any symptom excluding injection site symptoms	386 (41.0)	42 (50.6)	0.114	664 (70.7)	60 (72.3)	0.86
Pain at injection site	554 (58.4)	56 (67.5)	0.134	677 (71.3)	58 (69.9)	0.877
≤2 days	266 (48.0)	34 (60.7)	0.17	353 (52.1)	34 (58.6)	0.52
2-7 days	284 (51.3)	22 (39.3)		318 (47.0)	24 (41.4)	
>7 days	4 (0.7)	0 (0.0)		6 (0.9)	0 (0.0)	
Fever or chills	86 (9.1)	22 (26.5)	<0.001	377 (39.8)	33 (39.8)	1.0
≤2 days	4 (4.7)	1 (4.5)	-	13 (3.4)	2 (6.1)	0.72
2-7 days	82 (95.3)	21 (95.5)		363 (96.3)	31 (93.9)	
>7 days	0 (0.0)	0 (0.0)		1 (0.3)	0 (0.0)	
Fatigue or malaise	268 (28.2)	29 (34.9)	0.243	578 (61.0)	48 (57.8)	0.648
≤2 days	34 (12.7)	2 (6.9)	0.46	87 (15.1)	7 (14.6)	0.50
2-7 days	228 (85.1)	27 (93.1)		475 (82.2)	41 (85.4)	
>7 days	6 (2.2)	0 (0.0)		16 (2.8)	0 (0.0)	
Headache, dizziness or lightheadedness	200 (21.1)	22 (26.5)	0.315	421 (44.6)	30 (36.1)	0.172
≤2 days	31 (15.5)	0 (0.0)	0.13	42 (10.0)	4 (13.3)	0.84
2-7 days	164 (82.0)	21 (95.5)		366 (86.9)	25 (83.3)	
>7 days	5 (2.5)	1 (4.5)		13 (3.1)	1 (3.3)	
Eye, ear, mouth, or throat changes	21 (2.2)	2 (2.4)	1.0	31 (3.3)	3 (3.6)	1.0
≤2 days	5 (23.8)	0 (0.0)	0.68	4 (12.9)	2 (66.7)	0.06
2-7 days	15 (71.4)	2 (100.0)		24 (77.4)	1 (33.3)	
>7 days	1 (4.8)	0 (0.0)		3 (9.7)	0 (0.0)	
Swollen lymph node, skin/nail, or face changes	8 (0.8)	2 (2.4)	0.417	56 (5.9)	1 (1.2)	0.122
≤2 days	2 (25.0)	1 (50.0)	0.44	25 (44.6)	1 (100.0)	0.55
2-7 days	2 (25.0)	1 (50.0)		22 (39.3)	0 (0.0)	

>7 days	4 (50.0)	0 (0.0)		9 (16.1)	0 (0.0)	
Cough, chest, or breathing symptoms	19 (2.0)	1 (1.2)	0.928	32 (3.4)	0 (0.0)	0.171
≤2 days	5 (26.3)	0 (0.0)	0.75	9 (28.1)	0 (0.0)	-
2-7 days	12 (63.2)	1 (100.0)		20 (62.5)	0 (0.0)	
>7 days	2 (10.5)	0 (0.0)		3 (9.4)	0 (0.0)	
Nausea, vomiting, diarrhea, or other digestive symptoms	26 (2.7)	6 (7.2)	0.053	129 (13.6)	10 (12.0)	0.82
≤2 days	4 (15.4)	0 (0.0)	0.43	17 (13.2)	1 (10.0)	0.84
2-7 days	20 (76.9)	6 (100.0)		109 (84.5)	9 (90.0)	
>7 days	2 (7.7)	0 (0.0)		3 (2.3)	0 (0.0)	
Muscle, bone, joint, or nerve symptoms	107 (11.3)	13 (15.7)	0.311	304 (32.1)	26 (31.3)	0.987
≤2 days	13 (12.1)	1 (7.7)	0.50	40 (13.2)	5 (19.2)	0.40
2-7 days	86 (80.4)	12 (92.3)		250 (82.2)	21 (80.8)	
>7 days	8 (7.5)	0 (0.0)		14 (4.6)	0 (0.0)	
Memory or mood change	11 (1.2)	1 (1.2)	1.0	23 (2.4)	3 (3.6)	0.765
≤2 days	2 (18.2)	0 (0.0)	0.76	8 (34.8)	2 (66.7)	0.51
2-7 days	7 (63.6)	1 (100.0)		11 (47.8)	1 (33.3)	
>7 days	2 (18.2)	0 (0.0)		4 (17.4)	0 (0.0)	
Sleep changes	28 (3.0)	5 (6.0)	0.231	95 (10.0)	6 (7.2)	0.53
≤2 days	3 (10.7)	0 (0.0)	0.67	17 (17.9)	1 (16.7)	0.80
2-7 days	24 (85.7)	5 (100.0)		70 (73.7)	4 (66.7)	
>7 days	1 (3.6)	0 (0.0)		8 (8.4)	1 (16.7)	

Listed percentages for each symptom represent percent of entire respective subpopulation. Percentages for duration represent percent of symptomatic subpopulation in each timeframe.

*Chi-Square or ANOVA for comparison of any presence of each symptom and duration of symptoms, respectively.

Supplemental Table 4. Self-reported symptoms following first and second dose of Pfizer-BioNTech SARS-CoV-2 vaccine, by race and ethnicity.

	Post-Dose 1						Post-Dose 2					
	Hispanic (n=126)	Non-Hispanic Asian (n=280)	Non-Hispanic Black (n=33)	Other (n=100)	Non-Hispanic White (n=493)	P-value*	Hispanic (n=126)	Non-Hispanic Asian (n=280)	Non-Hispanic Black (n=33)	Other (n=100)	Non-Hispanic White (n=493)	P-value*
Any symptom, n (%)	74 (59.7)	164 (59.4)	20 (60.6)	57 (57.0)	299 (60.9)	0.964	87 (69.6)	198 (71.2)	23 (71.9)	74 (75.5)	370 (75.7)	0.534
Any symptom excluding injection site symptoms	59 (47.6)	123 (44.6)	16 (48.5)	41 (41.0)	189 (38.5)	0.248	81 (64.8)	191 (68.7)	23 (71.9)	73 (74.5)	356 (72.8)	0.357
Fever or chills	13 (10.3)	38 (13.6)	5 (15.2)	8 (8.0)	44 (8.9)	0.235	35 (27.8)	109 (38.9)	11 (34.4)	46 (46.0)	209 (42.4)	0.026
≤2 days	1 (7.7)	4 (10.5)	0 (0.0)	0 (0.0)	0 (0.0)	-	2 (5.7)	3 (2.8)	0 (0.0)	1 (2.2)	9 (4.3)	0.30
2-7 days	12 (92.3)	34 (89.5)	5 (100.0)	8 (100.0)	44 (100.0)		33 (94.3)	106 (97.2)	11 (100.0)	44 (95.7)	200 (95.7)	
>7 days	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	0 (0.0)	1 (2.2)	0 (0.0)	
Fatigue or malaise	36 (28.6)	92 (32.9)	15 (45.5)	31 (31.0)	123 (24.9)	0.033	65 (51.6)	165 (58.9)	20 (60.6)	67 (68.4)	309 (62.7)	0.092
≤2 days	7 (19.4)	11 (12.0)	2 (13.3)	2 (6.5)	14 (11.4)	0.712	11 (16.9)	17 (10.3)	2 (10.0)	19 (28.4)	45 (14.6)	0.002
2-7 days	29 (80.6)	79 (85.9)	12 (80.0)	28 (90.3)	107 (87.0)		50 (76.9)	147 (89.1)	16 (80.0)	46 (68.7)	257 (83.2)	
>7 days	0 (0.0)	2 (2.2)	1 (6.7)	1 (3.2)	2 (1.6)		4 (6.2)	1 (0.6)	2 (10.0)	2 (3.0)	7 (2.3)	
Headache, dizziness or lightheadedness	34 (27.2)	66 (23.7)	8 (24.2)	21 (21.0)	93 (18.9)	0.253	52 (41.3)	112 (40.3)	14 (42.4)	49 (49.0)	224 (45.6)	0.447
≤2 days	5 (14.7)	8 (12.1)	1 (12.5)	5 (23.8)	12 (12.9)	0.241	8 (15.4)	8 (7.1)	2 (14.3)	4 (8.2)	24 (10.7)	0.066
2-7 days	28 (82.4)	57 (86.4)	6 (75.0)	14 (66.7)	80 (86.0)		40 (76.9)	102 (91.1)	10 (71.4)	44 (89.8)	195 (87.1)	
>7 days	1 (2.9)	1 (1.5)	1 (12.5)	2 (9.5)	1 (1.1)		4 (7.7)	2 (1.8)	2 (14.3)	1 (2.0)	5 (2.2)	
Eye, ear, mouth, or throat changes	5 (4.0)	5 (1.8)	1 (3.0)	1 (1.0)	11 (2.2)	0.587	3 (2.4)	12 (4.3)	3 (9.1)	4 (4.0)	12 (2.4)	0.203
≤2 days	1 (20.0)	2 (40.0)	0 (0.0)	1 (100.0)	1 (9.1)	0.284	0 (0.0)	3 (25.0)	1 (33.3)	0 (0.0)	2 (16.7)	0.845
2-7 days	3 (60.0)	3 (60.0)	1 (100.0)	0 (0.0)	10 (90.9)		3 (100.0)	8 (66.7)	2 (66.7)	3 (75.0)	9 (75.0)	
>7 days	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)		0 (0.0)	1 (8.3)	0 (0.0)	1 (25.0)	1 (8.3)	
Swollen lymph node, skin/nail, or face changes	2 (1.6)	4 (1.4)	1 (3.0)	1 (1.0)	2 (0.4)	0.377	6 (4.8)	11 (3.9)	0 (0.0)	6 (6.0)	34 (6.9)	0.262
≤2 days	0 (0.0)	1 (25.0)	1 (100.0)	1 (100.0)	0 (0.0)	0.573	2 (33.3)	3 (27.3)	0 (0.0)	2 (33.3)	19 (55.9)	-
2-7 days	1 (50.0)	1 (25.0)	0 (0.0)	0 (0.0)	1 (50.0)		3 (50.0)	6 (54.5)	0 (0.0)	4 (66.7)	9 (26.5)	
>7 days	1 (50.0)	2 (50.0)	0 (0.0)	0 (0.0)	1 (50.0)		1 (16.7)	2 (18.2)	0 (0.0)	0 (0.0)	6 (17.6)	
Cough, chest, or breathing symptoms	4 (3.2)	4 (1.4)	1 (3.0)	3 (3.0)	8 (1.6)	0.653	4 (3.2)	14 (5.0)	0 (0.0)	4 (4.0)	10 (2.0)	0.16
≤2 days	2 (50.0)	1 (25.0)	0 (0.0)	1 (33.3)	1 (12.5)	0.841	2 (50.0)	4 (28.6)	0 (0.0)	1 (25.0)	2 (20.0)	-
2-7 days	2 (50.0)	2 (50.0)	1 (100.0)	2 (66.7)	6 (75.0)		2 (50.0)	9 (64.3)	0 (0.0)	3 (75.0)	6 (60.0)	
>7 days	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	1 (12.5)		0 (0.0)	1 (7.1)	0 (0.0)	0 (0.0)	2 (20.0)	

Nausea, vomiting, diarrhea, or other digestive symptoms	4 (3.2)	10 (3.6)	3 (9.1)	3 (3.0)	12 (2.4)	0.30	18 (14.3)	33 (11.8)	7 (21.2)	16 (16.0)	65 (13.2)	0.552
≤2 days	1 (25.0)	2 (20.0)	0 (0.0)	0 (0.0)	1 (8.3)	0.209	4 (22.2)	3 (9.1)	1 (14.3)	1 (6.2)	9 (13.8)	0.155
2-7 days	3 (75.0)	8 (80.0)	2 (66.7)	2 (66.7)	11 (91.7)		13 (72.2)	30 (90.9)	5 (71.4)	14 (87.5)	56 (86.2)	
>7 days	0 (0.0)	0 (0.0)	1 (33.3)	1 (33.3)	0 (0.0)		1 (5.6)	0 (0.0)	1 (14.3)	1 (6.2)	0 (0.0)	
Muscle, bone, joint, or nerve symptoms	18 (14.3)	41 (14.7)	4 (12.1)	10 (10.0)	47 (9.5)	0.216	35 (28.0)	81 (28.9)	16 (48.5)	34 (34.0)	164 (33.3)	0.147
≤2 days	1 (5.6)	6 (14.6)	0 (0.0)	3 (30.0)	4 (8.5)	0.158	3 (8.6)	15 (18.5)	0 (0.0)	6 (17.6)	21 (12.8)	0.058
2-7 days	14 (77.8)	34 (82.9)	3 (75.0)	6 (60.0)	41 (87.2)		27 (77.1)	64 (79.0)	15 (93.8)	27 (79.4)	138 (84.1)	
>7 days	3 (16.7)	1 (2.4)	1 (25.0)	1 (10.0)	2 (4.3)		5 (14.3)	2 (2.5)	1 (6.2)	1 (2.9)	5 (3.0)	
Memory or mood change	1 (0.8)	0 (0.0)	2 (6.1)	2 (2.0)	7 (1.4)	0.024	2 (1.6)	8 (2.9)	1 (3.0)	6 (6.0)	9 (1.8)	0.164
≤2 days	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (28.6)	-	1 (50.0)	3 (37.5)	0 (0.0)	2 (33.3)	4 (44.4)	0.623
2-7 days	1 (100.0)	0 (0.0)	1 (50.0)	1 (50.0)	5 (71.4)		1 (50.0)	4 (50.0)	0 (0.0)	3 (50.0)	4 (44.4)	
>7 days	0 (0.0)	0 (0.0)	1 (50.0)	1 (50.0)	0 (0.0)		0 (0.0)	1 (12.5)	1 (100.0)	1 (16.7)	1 (11.1)	
Sleep changes	6 (4.8)	10 (3.6)	2 (6.1)	3 (3.0)	12 (2.4)	0.574	9 (7.1)	22 (7.9)	2 (6.1)	15 (15.0)	53 (10.8)	0.177
≤2 days	0 (0.0)	1 (10.0)	0 (0.0)	1 (33.3)	1 (8.3)	0.016	0 (0.0)	6 (27.3)	0 (0.0)	7 (46.7)	5 (9.4)	<0.001
2-7 days	6 (100.0)	9 (90.0)	1 (50.0)	2 (66.7)	11 (91.7)		5 (55.6)	15 (68.2)	1 (50.0)	7 (46.7)	46 (86.8)	
>7 days	0 (0.0)	0 (0.0)	1 (50.0)	0 (0.0)	0 (0.0)		4 (44.4)	1 (4.5)	1 (50.0)	1 (6.7)	2 (3.8)	

Listed percentages for each symptom represent percent of entire respective subpopulation. Percentages for duration represent percent of symptomatic subpopulation in each timeframe.

*Chi-Square or ANOVA for comparison of any presence of each symptom and duration of symptoms, respectively.